By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Life Science Nation (LSN) is excited to welcome Bayer Co.Lab as a Title Sponsor of RESI Boston 2026, taking place September 22-23 at the Westin Copley Place in Boston, with virtual partnering continuing September 25 and 28-29.
Bayer Co.Lab is Bayer’s global network of life science incubators supporting early-stage entrepreneurs developing breakthrough technologies. By connecting emerging companies with scientific expertise, mentorship, infrastructure, and Bayer’s broader global network, Co.Lab provides an environment designed to help innovators advance promising science and build the relationships needed for future growth.
Bayer Co.Lab’s mission is closely aligned with RESI’s focus on connecting early-stage life science and healthcare companies with investors, strategic partners, and industry leaders who can accelerate breakthrough therapies.
Bayer Co.Lab’s will be sponsoring a 2-hour session at RESI Boston 2026:
Connecting Asian Biotech Innovation with Global Partners: A Bayer Co.Lab Showcase
Tuesday, September 22, 2:00 – 4:00pm EST
The showcase will bring seven emerging biotechnology companies from Korea and Japan to the RESI stage, highlighting innovative approaches across various therapeutic modalities.
| RSVP for Bayer Co.Lab Showcase |
artiCure | Korea
Tumor-selective replicating gene therapy targeting solid tumors
Crafton Biotechnology | Japan
mRNA therapeutics supported by advanced computational approaches
Curigin | Korea
RNA-based therapeutic technologies across multiple disease areas
Elisigen | Korea
Next-generation gene therapy with programs in ophthalmology
Genome & Company | Korea
Microbiome-driven therapeutic discovery and development
ILIAS Biologics | Korea
Exosome-based therapeutics for inflammatory and fibrotic diseases
Kanjin Therapeutics | Japan
RNA therapeutics, including siRNA and antisense approaches, for areas of unmet medical need
The program reflects a growing opportunity to connect promising innovation emerging from Asian biotech ecosystems with global pharmaceutical partners, investors, and other strategic collaborators. By bringing Korean and Japanese companies directly into the RESI community, the showcase will create a forum for companies to present their science, build international relationships, and explore pathways for global development and partnership.
Meet Bayer at RESI Boston
Bayer will have a strong presence at RESI Boston, with senior representatives spanning Co.Lab and BD & Licensing departments.
 Alberto Nobili Sr. Director, Strategy and Portfolio at Co.Lab |
 Nobuhiro Kazama Head of Collaborate to Cure Japan Hub |
 Ilona Gutcher Senior Director, BD&L Oncology |
 Carla Klattenhoff Senior Director / Scientific US Lead for Research and Early Development in CV, Renal and Immunology |
 Shivaranjani Sridharan Executive Director, Business Development & Licensing |
Their participation gives RESI attendees an opportunity to engage with Bayer leaders representing multiple areas of scientific and strategic interest and to gain greater insight into how a global pharmaceutical company approaches external innovation and collaboration.
Bringing Global Innovators Together in Boston
RESI has always been built around a simple idea: great science can come from anywhere, but moving it forward requires the right connections.
Bayer Co.Lab’s participation as Title Sponsor of RESI Boston 2026 reinforces that mission. From supporting emerging entrepreneurs to creating new connections between Asian biotech innovators and the global life science ecosystem, the collaboration will bring another important dimension to this year’s RESI Boston.
Join Bayer Co.Lab and the global early-stage life science community at RESI Boston 2026!
Next Phase Newsletter 